AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute

   Press Release

Vancouver, BC and Montréal, QC (November 18, 2021) – adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.

Open to a maximum of 20 participants annually, the Executive Institute has become the standard for leadership training in life sciences. It is custom designed to help C‑suite and executive-level professionals strengthen their life science leadership skills and enhance their strategic abilities. The overarching goal of this, and all adMare Academy programs, is to build the talent that Canada needs to ensure a healthy and growing life sciences industry.

The members of the new Executive Institute cohort are:

  • Sherry Aulin, Chief Financial Officer, Xenon Pharmaceuticals Inc.; BC
  • Mike Cooke, CEO, Co-Founder, AmacaThera; ON
  • Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs, Medicago Inc.; QC
  • Lorrie Deyelle, Chief Human Resources Officer, Medicago Inc.; QC
  • James Doyle, CEO, Modelis Inc.; QC
  • Natalie J. Galant, CEO, Co-Founder, Paradox Immunotherapeutics; ON
  • Christopher Kendall, Vice President Finance and FP&A, Repare Therapeutics; QC
  • Guy Le Houillier, General Manager, Domain Therapeutics; QC
  • Edmond Lee, Senior Director, New Product Planning and Business Operations, Microbion Pharma Corp.; BC
  • Sarah Marquis, Vice President, Legal Affairs and Corporate Secretary, Medicago Inc.; QC
  • Stephen Morris, Vice President of Cancer Biology, Repare Therapeutics; QC
  • Elizabeth Nanak, CEO, Canadian Glycomics Network (GlycoNet); AB
  • Nicolas Petit, Vice President, Commercial Operations, Medicago Inc.; QC
  • Hilary Pierce, CEO, Co-Founder, Total Flow; BC
  • Julia Pomoransky, Director, Business Development, Turnstone Biologics; ON
  • Louise St-Onge, Head, Market Access and Government Affairs, Rare Diseases, Mitsubishi Tanabe Pharma; ON
  • Anitha Thomas, Director — Delivery, Precision Nanosystems; BC
  • Michael Wilson, CEO, DrugBank; AB.

Canada has a wealth of life science knowledge and growing businesses. Strong leadership is most critical to scaling these companies into global anchors,” said Erin Stashin, Director of the adMare Academy. Our Executive Institute is recognized as enabling participants to maximize their personal leadership, accelerate their organizations’ goals, commitment, alignment and results, and ultimately continue to build the Canadian industry. We look forward to working with this impressive new group of individuals.”

The Executive Institute is delivered in partnership with the Centre for Creative Leadership and with the generous support of Pfizer Canada.

- 30 -

About adMare BioInnovations

With a wealth of scientific discovery, Canada is primed to be a global leader in life sciences. To make this a reality, adMare uses its scientific and commercial expertise, specialized infrastructure, and investment capital to build new companies, robust ecosystems and industry-ready talent – and re-invests into the Canadian industry to ensure it is sustained for the long-term. Our 25+ portfolio companies have attracted more than $1.4 billion of investment, have a combined value of over $3 billion, and employ more than 900 Canadians. The adMare Academy has trained more than 500 alumni – 95% of whom are employed in the Canadian life sciences industry.

To learn more about the adMare Academy’s Executive Institute, reach out to our team via training@​admarebio.​com or visit our website at www​.admarebio​.com/​a​d​m​a​r​e​-​a​c​a​d​e​m​y​/​e​x​e​c​u​t​i​v​e​-​i​n​s​t​i​tute/

For additional information, please contact:

Gino Calabretta
Senior Manager, Communications
(438) 998‑2676
gcalabretta@​admarebio.​com


Disponible en français

More Recent News

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

   Press Release

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

   Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

New study setting the stage for non-opioid analgesic in post-surgical pain management

   Press Release

AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more

Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

416-360-2094
MaRS Centre, West Tower,
661 University Ave Suite 1300,
Toronto, ON M5G 0B7

[email protected]